Sign in
Taking people in United StatesPhase 1

Tests two treatments together in melanoma and synovial sarcoma

Tests IMA203 with mRNA-4203 in adults with advanced melanoma or synovial sarcoma.

Key facts

Who runs it
Immatics US, Inc.
Where
Boston, Houston, New York, and San Francisco, United StatesSee the 4 sites
Trial code
Registry title
ACTengine® IMA203 Combined With mRNA-4203
Status
Recruiting
Phase
Phase 1
People taking part
15 people, planned
Started
25 Jul 2025
Expected to end
Aug 2029
Type of study
Interventional
Treatments tested
  • IMA203
  • mRNA-4203
Record updated
8 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cutaneous melanoma or synovial sarcoma that cannot be removed by surgery or has spread, and that was treated before.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Cutaneous melanoma or synovial sarcoma, confirmed by tests, that cannot be removed by surgery or has spread. The disease must be measurable by RECIST 1.1. ECOG performance status 0-1.
Earlier treatment
Melanoma: the disease got worse, or treatment caused side effects, on or after at least one PD-1 inhibitor. Synovial sarcoma: at least one earlier line of treatment (or the person declined it) and still needing more systemic therapy.
Biomarker or test result
HLA-A*02:01 positive.

Main reasons for not taking part

  • Another cancer within the last 3 years (with some exceptions)
  • Pregnant or breastfeeding
  • Serious autoimmune disease
  • Earlier allogenic stem cell or solid organ transplant
  • HIV infection, or active hepatitis B or hepatitis C

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Pathologically confirmed and documented cutaneous melanoma (CM) or synovial sarcoma (SS) with unresectable or metastatic disease
  • HLA-A*02:01 positive
  • Adequate selected organ function per protocol
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
  • Life expectancy more than 5 months
  • CM participants who must have disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor
  • SS participants must have received (or declined) at least one line of treatment (including SoC) and are still in need of further systemic therapy
  • Female participants of childbearing potential must use adequate contraception prior to trial entry until 12 months after the infusion of IMA203 and 15 days after the last mRNA 4203 dose administration; Other protocol defined inclusion criteria could apply

Who cannot take part

  • Prior allogenic stem cell transplantation or solid organ transplantation
  • Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
  • Participants with active brain metastases prior to lymphodepletion
  • Concurrent treatment in another clinical trial or a device trial that could interfere with the IMA203 treatment
  • History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
  • Serious autoimmune disease
  • History of cardiac conditions as per protocol
  • History of hypersensitivity to cyclophosphamide, fludarabine, or IL-2
  • History of hypersensitivity to mRNA-based medicines
  • Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection
  • Any condition contraindicating leukapheresis
  • Participants with renal impairment AND reduced bone marrow reserve per protocol; Other protocol defined exclusion criteria could apply
  • Pregnant or breastfeeding
  • Participants with lactate dehydrogenase (LDH) greater than threshold allowed per protocol

Where in United States

  • Dana-Farber Cancer InstituteBoston, United StatesContact: Karam Khaddour, MDTaking people
  • MD Anderson Cancer CenterHouston, United StatesContact: Dejka Araujo, MDTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: James Smithy, MDTaking people
  • University of California San FranciscoSan Francisco, United StatesContact: Adil Daud, MDTaking people

About the trial

What the trial wants to find out

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

The group in the trial

  • IMA203 with mRNA-4203 in participants with metastatic cutaneous melanoma or synovial sarcomaTreatment being tested

    This is a non-comparative, open-label trial with different cohorts investigating IMA203 in combination with mRNA-4203.

    Treatment: IMA203 and mRNA-4203

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)
Plain-language title
Tests two treatments together in melanoma and synovial sarcomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 January 2026